Key Considerations for Smaller Biotechs in APAC Phase III Trials
- Smaller biotechs must align country selection with marketing authorization plans to succeed in APAC Phase III trials.
- Choosing the right sites and partnering with a CRO that has regional experience and KOL networks are critical for effective trial execution.
Operational Impact
Smaller biotechs can leverage faster recruitment and lower costs in APAC, particularly in oncology, to improve trial outcomes.
Source: Applied Clinical Trials RSS